AC Immune (ACIU) Jefferies London Healthcare Conference 2025 summary

Pipeline overview and strategic focus

• Pipeline includes three phase two active immunotherapy programs and a phase three diagnostic, with key assets partnered with major pharmaceutical companies and fast-track FDA designations.

• Precision medicine and prevention are central, targeting neurodegenerative diseases with both active immunotherapies and small molecules validated in clinical and business development.

• Partnerships have generated over $430 million, with potential for more than $4 billion in future milestones and royalties; cash runway extends to Q3 2027.

Scientific and clinical advancements

• Small molecule programs target intracellular misfolded proteins, showing strong brain penetration and specificity, with oral administration for broad applicability.

• Tau morphomer 664 reduced tau pathology by over 50% and neurotoxicity in aggressive mouse models, indicating preventive potential in Alzheimer's disease.

• NLRP3 inhibitors demonstrated high potency, safety, and significant reduction in neuroinflammation and neurotoxicity markers in preclinical models.

Milestones and upcoming data

• Phase two ABATE trial with Takeda will release 12-month data in December, with further cohort updates expected.

• Wholly owned ACI-7104 (alpha-synuclein immunotherapy) will report immunogenicity, biomarker, pharmacodynamic, and clinical outcome data by year-end.

• IND/CTA submissions for small molecule clinical leads are planned for December, with clinical trials starting early next year.